{
  "name" : "dacemirror.sci-hub.se_journal-article_a632a9f86a80c7bee6e400717f2d6fbf_fan2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "A New Generation of NIR-II Probes: Lanthanide-Based Nanocrystals for Bioimaging and Biosensing",
    "authors" : [ "Yong Fan", "Fan Zhang" ],
    "emails" : [ "zhang_fan@fudan.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "PROGRESS REPORT\n1801417 (1 of 14) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advopticalmat.de"
    }, {
      "heading" : "A New Generation of NIR-II Probes: Lanthanide-Based",
      "text" : ""
    }, {
      "heading" : "Nanocrystals for Bioimaging and Biosensing",
      "text" : ""
    }, {
      "heading" : "Yong Fan and Fan Zhang*",
      "text" : "DOI: 10.1002/adom.201801417"
    }, {
      "heading" : "1. Introduction",
      "text" : "Recently, fluorescence imaging has been extensively studied and used in life sciences and medical research due to its fast feedback, high sensitivity, and high spatiotemporal resolution.[1–4] In addition, it does not require hazard ionizing radiation, as compared to routine imaging modalities, such as computed tomography (CT),[5–8] positron emission tomography (PET),[7–9] and single-photon emission computed tomography (SPECT).[6,8,10] It is also known as a noninvasive technique, enabling the real-time acquisition of wide-field images. Despite many advantages, key issues in optical imaging lie in the high absorption and scattering of biological tissues as well as high autofluorescence (Figure 1A), leading to low tissue penetration depth and low signal-to-noise ratio (SNR). This is especially evident in the traditional visible range (VIS, 400–700 nm),[1,11,12] which is only feasible for superficial tissues imaging with penetration depth at ≈1 mm. Subsequently, imaging in the first near-infrared window (NIR-I, 700–900 nm),[11,13] traditionally defined as biological transparency window, shows an improved penetration depth with up to several millimeters in biological imaging due to the reduced absorption and scattering coefficient (Figure 1B,C), as photon scattering in biological tissue scaling with λ−ω (λ denotes the wavelength, ω = 0.22–1.68 depending on tissues).[11] Although fundamental researches\nFluorescence-based imaging in the second near infrared window (NIR-II, 1000–1700 nm) is extensively used in both fundamental scientific research and clinical practice, owing to its advances of high sensitivity and high spatiotemporal resolution with increasing tissue penetration depths. Among several NIR-II fluorophores, recent accomplishments in biocompatible lanthanidebased luminescent nanomaterials have aroused great interest of researchers. This progress report summarizes recent progress in controlled synthesis of lanthanide-based NIR-II nanomaterials and their state-of-the-art in NIR-II biomedical imaging and biosensing applications. In addition, challenges and opportunities for this kind of novel NIR-II nanoprobes are also discussed."
    }, {
      "heading" : "Fluorescence-Based Bioimaging",
      "text" : "Dr. Y. Fan, Prof. F. Zhang Department of Chemistry Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials State Key Laboratory of Molecular Engineering of Polymers and iChem Fudan University Shanghai 200433, P. R. China E-mail: zhang_fan@fudan.edu.cn\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adom.201801417.\nand clinical applications have been applied to this optical window,[14–19] especially utilizing the US Food and Drug Administration (FDA) approved indocyanine green (ICG) for the last several decades,[17–19] there is still plenty of room to be improved for obtaining high-quality images because of the remaining tissue autofluorescence and background interference (Figure 1D).\nTo overcome the constraints of imaging in NIR-I region, a new imaging window, namely the second near-infrared window (NIR-II, 1000–1700 nm), has been identified recently after predicted through optical simulations.[11,13] In addition to the\nfurther reduced scattering coefficient at a fixed tissue depth as that in NIR-I region, tissue autofluorescence in NIR-II region decreases exponentially and is almost zero when the wavelength is beyond ≈1500 nm (Figure 1D).[20] Although light absorption of various biological tissues in NIR-II region is slightly higher than that in NIR-I region (Figure 1C), the benefits of much reduced scattering loss and near-zero autofluorescence can dramatically enhance spatial resolution, SNR, and penetration depth in NIR-II imaging. For example, small-vessel NIR-II imaging at 1–3 mm deep in the hind limb of mouse was performed with ≈30 µm spatial and <200 ms per frame temporal resolution, which was unattainable by traditional NIR-I imaging or CT.[21] In another work of imaging of the hind lymph system, the SNR of the lymph vessel based on NIR-II imaging was improved from 3.3, 7.3 to 10.5 by increasing the emission wavelengths from 1100, 1300 to 1500 nm, which were all higher than those obtained with VIS (SNR = 1.4 at 520 nm) and NIR-I imaging (SNR = 1.3 at 720 nm).[22] To date, NIR-II imaging has generated escalating interests and is becoming an exciting and fast-growing field.\nSince NIR-II window is recognized as one of the optimal regions for optical bioimaging, developing fluorescence probes capable of NIR-II emissions has become an urgent task. Although available NIR-II fluorophores are of relative scarcity, so far there are four kinds of candidates studied: quantum dots (QDs),[23–25] single-walled carbon nanotubes (SWNTs),[26–28] organic dye molecules,[29,30] and conjugated polymers.[31] However, the aforementioned fluorophores suffer from some major limitations. For example, QDs contain undesirable toxic elements, such as lead, mercury, or arsenic.[25] SWNTs exhibit broad emission distribution, spanning hundreds of nanometers with optical excitation wavelength deviating from NIR window. Organic dye molecules usually suffer from low photostability under both air and light irradiation, and small Stokes shift.[29] Besides, these molecules, as well as conjugated polymers, also have low solubility in aqueous solution. In contrast,\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (2 of 14)\nwww.advopticalmat.de\nlanthanide-based nanocrystals as a new generation of NIR-II probes, with low photobleaching, long luminescence lifetimes, low long-term cytotoxicity and narrow emission band widths, have gained more attention recently for bioimaging applications. Although rather new in this NIR-II imaging field, lanthanide-based nanocrystals have already demonstrated the feasibility and prospect in NIR-I biological applications with lower background and higher penetration depth using commercially silicon detector.[15,16] Nevertheless, the limitation is that only Nd3+ (between 850 and 900 nm, 4F3/2→4I9/2) and Tm3+ (between 750 and 850 nm, 3H4→3H6) are able to emit in this window under 800 and 980 nm (with the Yb3+ bridging ion), respectively, which hinders the multiplexed bioimaging and detection. As InGaAs camera with high response at wavelength in the NIR-II window becomes available due to the development of military and industry, bioimaging employing lanthanide-based nanocrystals may extend and focus on this much newer imaging field for not only the advantages of NIR-II imaging mentioned above, but also more wavelengths of lanthanide-based nanocrystals in this window to be chosen. Table 1 summarizes the typical lanthanide-based NIR-II nanocomposites. More importantly, recent advances enable these nanocrystals to be synthesized with accurate control of composite, uniform size, crystal phase, morphology, and emission colors. Therefore, in this progress report, we provide the recent progress of bioimaging and biosensing based on lanthanidebased NIR-II nanocrystals and then discuss their challenges and opportunities."
    }, {
      "heading" : "2. Mechanisms of Lanthanide-Based Nanocrystals Emitting in NIR-II Region",
      "text" : "In lanthanide-based NIR-II nanocrystals, three components are commonly included: a host matrix, a sensitizer, and an activator. Except for the host matrix, which needs to be optical transparent and has low lattice phonon energy, the rational choice of different lanthanide ions (Ln3+) as the sensitizer and activator is also a key factor for efficient NIR-II emissions. So far, Nd3+, Yb3+, and Er3+ are demonstrated to be efficient sensitizers due to their large absorption cross-sections in NIR-I or NIR-II region (Figure 2A). Meanwhile, several Ln3+ (Ln = Pr, Nd, Ho, Er, and Tm) featuring ladder-like arranged energy levels are reported and extensively explored as activators emitting in NIR-II region (Figure 2A). Generally, NIR-II emissions based on lanthanide nanocrystals can be realized through four mechanisms: a) intrinsic emissions from Nd3+ or Er3+ after absorbing the excitation photons (Figure 2B); b) emissions from Ln3+ activators (Ln = Ho, Pr, Tm, or Er) after absorbing energy transferred from a sensitizer Yb3+, named as Yb3+–Ln3+ pair (Figure 2C); c) using Nd3+ as a sensitizer to transfer absorbed energy to Ln3+ activators ((Ln = Ho, Pr, Tm, or Er) through energy bridging from Yb3+, named as Nd3+–Yb3+–Ln3+ system (Figure 2D); d) emissions for Ln3+ activators (Ln = Nd, Ho, or Tm) using Er3+ as the sensitizer through upconversion process, named as Er3+–Ln3+ pair (Figure 2E).\nFor the case of intrinsic emissions from Nd3+- or Er3+-doped nanocrystals, Nd3+ or Er3+ is employed as both the sensitizer and activator. With 730, 808, or 860 nm illumination, Nd3+\nharvests the excitation photons with the generation of electrons in the 4I9/2 ground state upward transiting to the 4F7/2, 4F5/2, or 4F3/2 states, respectively. Then through nonradioactive relaxation, electrons in the 4F7/2, 4F5/2 states move back to the 4F3/2 states. Finally, two transition ways occur with emissions at 1060 nm (4F3/2→4I11/2) and 1330 nm (4F3/2→4I13/2) in the NIR-II region (left in Figure 2B). As for Er3+-doped nanocrystals, they can be excited by both 808 and 980 nm light, resulting in upward transition of 4I15/2→4I9/2 and 4I15/2→4I11/2, respectively. Then after electrons relax to the 4I13/2 states, emission at ≈1550 nm will be released following the radioactive relaxation of 4I13/2→4I15/2 (right in Figure 2B).\nIn Yb3+–Ln3+ pair, Yb3+ acts as the sensitizer which absorbs 980 nm light (2F7/2→2F5/2). Take Yb3+–Ho3+ pair as an example, the energy absorbed by Yb3+ is transferred to Ho3+ via 2F5/2 (Yb3+) +5I8 (Ho3+)→2F7/2 (Yb3+) +5I6 (Ho3+), resulting in the population of electrons on the 5I6 state of Ho3+. Then, down-shifting emission at 1155 nm of Ho3+ is generated through 5I6→5I8 (Figure 2C). In similar energy transfer pathways, down-shifting emissions in the NIR-II region can also be realized from Pr3+ at 1289 nm (1G4→3H5) and Er3+ at 1525 nm (4I13/2→4I15/2) (Figure 2C). With regard to Yb3+–Tm3+ pair, a two-photo upconversion process is needed to populate the higher energy state 3F2 and 3F3. Similarly, these states of Tm3+ are mostly depopulated following a nonradioactive route that populates the 3H4 state. Finally, the NIR-II emission at 1475 nm is then produced through 3H4→3F4 radioactive (Figure 2C). It should be noted that due to the upconvesion process of Yb3+–Tm3+ pair and densely\nYong Fan received his B.S. degree (2009) from Xi’an Jiaotong University and Ph.D. (2015) from Tsinghua University (China). Since then he has studied as a postdoctoral fellow at Fudan University. His current research interests focus on design and synthesis of functional inorganic nanomaterials and optical devices for bio-applications.\nFan Zhang received his Ph.D. in 2008 from Fudan University followed by more than two years postdoctoral experience in University of California at Santa Barbara before joining as a professor in the Chemistry Department of Fudan University in 2010. His current research interests include bioanalysis, bioimaging, drug delivery, and dis-\nease therapy. Prof. Zhang has authored a number of book chapters, patents, more than 100 peer-reviewed research papers in international journals, and two English books.\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (3 of 14)\nwww.advopticalmat.de\narranged energy states of Pr3+ in Yb3+–Pr3+ pair, the NIR-II emission efficiency of the two pairs are much less than the other two.[32]\nFor Nd3+–Yb3+–Ln3+ system, which is similar to the mechanism of Yb3+–Ln3+ pair, the energy transfer processes can be considered as (Nd3+–Yb3+)–Ln3+ pair. By introducing Nd3+, the excitation wavelength is able to be efficiently shifted from 980 to 808 nm. After populating the 4F3/2 state of Nd3+ by absorbing 808 nm light, the energy will be transferred to Yb3+ via 4F3/2 (Nd3+) +2F7/2 (Yb3+)→4I9/2 (Nd3+) +2F5/2 (Yb3+), populating the 2F5/2 of Yb3+.[33] Then Yb3+ will act as a translation ion and further transfer the energy to the activators as discussed in the Yb3+–Ln3+ pair above to emit in the NIR-II region (Figure 2B,D).\nExcept for intrinsic emitting and employed as the activator, Er3+ can also be adopted to sensitize other activators to release NIR-II emissions at another excitation band of 1525 nm (4I15/2→4I13/2), as in the form of Er3+–Ln3+ pair (Ln = Nd, Ho, or Tm)[34,35] (Figure 2E). To achieve this goal, a three-photon upconversion process is required to populate the energy state 4F5/2 of Nd3+, 5F5 of Ho3+ or 3F2 and 3F3 of Tm3+, respectively. After different nonradioactive radiation pathways, emissions at 1060 nm (Nd3+, 4F3/2→4F5/2), 1330 nm (Nd3+, 4F3/2→4I13/2), 1155 nm (Ho3+, 5I6→5I8), and 1475 nm (Tm3+, 3H4→3F4) are\ngenerated, respectively. Similarly, these pairs also exhibit fairly lower emission efficiencies due to the upconversion processes."
    }, {
      "heading" : "3. Synthesis of Lanthanide-Based NIR-II Nanocrystals",
      "text" : "With the development of nanotechnology, a variety of chemical techniques, including thermal decomposition, hydro(solvo)thermal synthesis, coprecipitation, and sol–gel process, have been demonstrated to synthesize lanthanide-based nanocrystals with controlled crystalline phases and sizes. Choosing facile and efficient synthesis methods is critical to the nanocrystals with properties matching the need for extended therapeutic and bioimaging applications envisioned. Readers may also refer to those recently published reviews on the synthetic method for more detailed information.[36–40] Herein, we focus on discussing some synthesis tips of the commonly used structures for efficient NIR-II emitting.\nAmong all the candidates, Nd3+-doped nanocrystals arise as pioneers for NIR-II imaging due to their easy fabrication procedures and nonheating excitation bands (730, 808, and 860 nm) in the biological transparency window. So far, an increasing number of research works on Nd3+-doped NIR-II\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (4 of 14)\nwww.advopticalmat.de\nnanocrystals with different host matrix has been reported, such as LaF3,[41] NaGdF4,[42] SrF2,[43] NaYF4,[44] and LiYF4.[45] To obtain the brightest fluorescence signal, the optimal Nd3+ concentrations are generally controlled between 1% and 5%,[41–45] since higher doping concentration will dramatically decrease the intensity due to the deleterious concentration quenching effects. In addition, surface quenching from defects or interactions with solvent molecules also hampers their optical efficiency, and thus passivated shells must be employed, which show beneficial influence and have been impressively demonstrated in many literatures.[42,44–47] Except for suppressing the energy-loss effects above, host matrix also plays a key role on optical properties of these nanocrystals. A comparative analysis of seven Nd3+-doped systems, including NaGdF4:Nd, LaF3:Nd, SrF2:Nd, KYF4:Nd, GdVO4:Nd, NaYF4:Nd, and Y3Al5O12:Nd has been performed recently.[48] The results showed that their fluorescence properties were remarkably different and appropriate host materials were needed to choose depending on the specific applications. For example, GdVO4:Nd nanocrystals were shown as optimum probes for in vivo NIR-I imaging, while NaYF4:Nd nanocrystals had been revealed as promising probes for autofluorescence-free imaging due to the highest 4F3/2→4I13/2 (1330 nm) branching ratio. Apart from Nd3+-doped nanocrystals, Er3+ has also been explored as an intrinsic emitter. The previous Er3+-doped nanocrystals, including NaYF4:Er, LiYF4:Er, or NaGdF4:Er, are mainly applied to photovoltaic devices by two- or three-phonon upconversion process to give emissions in the VIS (550 and 670 nm) or NIR region (800 and 970 nm) under excitation with telecom-wavelength at ≈1500 nm.[49–51] In these systems, Er3+ concentrations were confined to only 10–25% to provide highest emission efficiency. Until recently, an exciting work provided a direct evidence that the concentration quenching effect for NaY(Er)F4 was the energy migration to surface defects, rather than cross relaxation between dopant ions.[52] They demonstrated that a core/shell NaY(Er)F4@ NaLuF4 nanocrystals could greatly enhance the Er3+ emission\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (5 of 14)\nwww.advopticalmat.de\nat 1525 nm with both 800 and 980 nm excitations, in which the highest emission efficiency was obtained with 100% Er3+ doping.\nIn addition to the intrinsic emissions, recent efforts have also been made to explore other Ln3+ activators (Ln = Ho, Pr, Tm, or Er) to achieve NIR-II emissions using Yb3+ as the sensitizer codoped in the most efficient NaGdF4 or NaYF4 host.[32,53,54] Due to the concentration quenching effects and the contradictory impact of efficient resonant energy transfer from Yb3+ sensitizer to the Ln3+ activator, the optimal doping ratio of Yb3+/Ln3+ is needed to optimize to obtain the highest emission efficiencies in these Yb3+–Ln3+ pairs. However, increasing Yb3+ concentration (by substitution for Gd3+ or Y3+ in the host matrix) would inevitably lead to the particle size being uncontrollable.[55–58] This is because the heavy Yb3+ with smaller ionic radius (r = 1.125 Å)[59] than Gd3+ (r = 1.193 Å)[59] or Y3+ (r = 1.159 Å)[59] in NaGdF4 or NaYF4 host, respectively, tends to form larger nanocrystals owing to the higher crystal growth rate.[60] Therefore, the optical properties for different nanocrystal batches are essentially not comparable because of the size effect. To reduce this unfavorable influence, an optically inert Lu3+, which can closely mimic the effect of Yb3+, can be codoped to maintain the total concentration of Yb3+ and Lu3+ in the host.[55,58] The similar ionic radius and comparable chemical properties between Yb3+ and Lu3+ (r = 1.117 Å)[59] ensure a negligible effect of local crystallization distortion on the emission intensity, which helps to preserve the particle size under identical synthesis conditions. In addition, employing an inert core (NaGdF4 or NaYF4) as the seed for epitaxial growth of the outer emitting shell can also avoid appreciable variation in particle size caused by Yb3+\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (6 of 14)\nwww.advopticalmat.de\ntunability.[57,61,62] This core/shell structure enables the doping ratio of Yb3+/Ln3+ to be tuned at will while maintaining the controllable nanocrystal size and morphology. More recently, an exciting work successfully demonstrated a highly repeatable and controllable method for synthesis of small-sized hexagonal NaYbF4 nanocrystals without additional impurity doping.[63] By modulating the amounts of the solvent and ligand, the size of NaYbF4 nanocrystals can be easily tuned, facilitating the future applications of lanthanide-based nanocrystals. Apart from excitation at 980 nm by the Yb3+ sensitizer, recent studies have also focused on using Nd3+ as the sensitizer. However, the biggest challenge of using this new sensitizer is the harsh quenching effect caused by the energy back-transfer from Ln3+ activators to Nd3+. Thus, the Nd3+ doping concentration must be constrained below 1% to minimize quenching interactions in conventional tri-doping systems.[64] To solve this problem, a core/shell structure that separates Ln3+ activators and Nd3+ into core and shell is applied to increase the emission intensity, in which the Nd3+ concentration can be elevated to 10–20%.[65,66] To thoroughly block the quenching interactions for efficient emission, a transition layer doped with only Yb3+ was introduced in between the above core/shell structure to increase the Nd3+/Ln3+ interionic distance. Therefore, the Nd3+ concentration could be further increased as high as 90%.[67] Nevertheless, due to lattice mismatch between NaNdF4 and other main hosts (NaGdF4, NaYF4, or NaYbF4), the Nd3+ heavily doped core/multishell nanocrystals often show irregular morphology.\nMore recently, a new sensitizer Er3+ has also been reported and draw increasing interests to transfer the absorbed energy in NIR-II region (1532 nm) to the nearby Ln3+ activators (Ln = Nd, Ho, and Tm) for NIR-II emissions.[34,35] To build these pairs, heavily doped Er3+ is the guarantee to accumulate more excitation photons. Meanwhile, doping ratio of Er3+/Ln3+ is needed to be optimized to provide the highest emission efficiency. Due to the main energy loss (surface quenching effects) as mentioned above, the efficient energy transfer from Er3+ to Ln3+ can only be preserved by a thicker inert shell coating. However, the way that Er3+/Ln3+ codoping in the core is basically impractical to Nd3+ due to the severe cross-relaxation between Er3+ and Nd3+. Similar to the structure of above Nd3+–Yb3+–Ln3+ system, Er3+ and Nd3+ are also needed to be separated into core and shell to realize efficient NIR-II emission of Nd3+.[34]"
    }, {
      "heading" : "4. Lanthanide-Based NIR-II Nanocrystals for Biomedical Imaging",
      "text" : "In these new NIR-II probes, Yb3+ has been mainly employed as a highly promising and efficient sensitizer due to its large absorption cross-section at 980 nm (1.2 × 10−20 cm2).[65] Through the doping of different Ln3+ activators, such as Er3+, Tm3+, Ho3+, or Pr3+, in hexagonal NaYF4 host, the exceptional emission wavelength can be tuned over a broad range spanning the NIR-II region (Figure 3A,B).[32] Nevertheless, due to discrepancy in the resonant energy transfer efficiency from Yb3+ to the different Ln3+ activators, nanocrystals based on Yb3+–Er3+ pair have the highest optical efficiency and been thoroughly studied and applied to in vitro and in vivo bioimaging.[32,53,54,68–70] To increase the aqueous solubility, the NaYF4:Yb/Er nanocrystals could be embedded within human serum albumin (HSA) which showed strong accumulation in tumors and organs with micrometer resolution at millimeter depth (Figure 3C).[32] Besides, these nanocrystals with longer emission wavelength at 1525 nm permitted an improved resolution and a deeper penetration depth than that in NIR-I region (808 nm). Unlike other NIR-II probes (e.g., SWNT, QDs) with a wide emission bands in the range of ≈200–500 nm, lanthanide-based NIR-II nanocrystals also enabled in vivo multicolor imaging of xenograft tumors based on Ho3+ emission at 1185 nm and Er3+ emission at 1525 nm with narrow emission band width.[32] By comparing with other NIR-II fluorescent probes including IR1061, SWNTs, and PbS, NaYF4:Yb/ Er nanocrystals presented optimal biological and optical performance in the biodistribution, pharmacokinetics, and toxicities using a layer-by-layer platform (core/PLA/DXS/PLA/ HA).[70] In addition to the studies focused on Y3+ host, a new orthorhombic Sc-based host codoped with Yb3+/Er3+ possessed an increased NIR-II emission centered at 1525 nm with a high quantum yield (2.7%).[69] For further bioapplication, PAA was used through a ligand exchange method to convert the hydrophobic nanocrystals to the biocompatible probes. Due to the stronger NIR-II emission, these probes have demonstrated successful noninvasive through-skull brain angiography and highresolution abdomen blood vessels imaging with high spatial (down to 58.15 µm) and high temporal resolution.[69] Despite the much remarkable works on NIR-II imaging, Yb3+ sensitizer is not always the optimum choice which only absorbs excitation wavelength at ≈980 nm, overlapping well with the absorption peak of water (Figure 3D).[65] This will result in a risk of local temperature rise and substantial overheating, hindering further development of Yb3+ sensitized nanocrystals. To address this limitation, excitation wavelength should be controlled to minimize the heating effect for wide biological applications. Therefore, Nd3+–Yb3+–Ln3+ system was adopted. On one hand, Nd3+ has absorption cross-section at 808 nm ten-times higher than Yb3+ and with a high energy transfer efficiency from Nd3+ to Yb3+ (up to 70%).[33] On the other hand, Nd3+ has a much lower water absorption than Yb3+ (Figure 3D). Compared to 980 nm, a 60% weaker energy attenuation of 808 nm was observed after passing through water.[57] Based on different host matrix materials, the branch ratio of the Nd3+ emission at 1060 nm showed ≈3–35 times higher than that at 1330 nm.[48] Therefore, the 1060 nm wavelength has been applied to NIR-II bioimaging due to higher emission efficiency.[71] A big concern, however, is that the remaining of tissue autofluorescence also extends beyond 1060 nm, inhibiting the in vivo fluorescence imaging with high resolution. To eliminate the endogenous tissue autofluorescence for increasing SNR of fluorescence imaging, a time-gating imaging method was introduced by combining with long-lived fluorophores (µs–ms range), as compared with the short autofluorescence lifetime (≈1–10 ns for different type of tissue).[72] In addition, due to the negative correlation between autofluorescence intensity and emission wavelength, longer wavelength may be immune to the autofluorescence interference. For example, SrF2:Nd nanocrystals with a highly intense 1330 nm emission were reported and used for high contrast in vivo fluorescence imaging with much lower autofluorescence.[43] Apparently, zero-autofluorescence from biological\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (7 of 14)\nwww.advopticalmat.de\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (8 of 14)\nwww.advopticalmat.de\ntissues can be acquired by further extending the emission to a subregion in NIR-II window from 1500 to 1700 nm.[20] And not only that, this sub-region favors much suppressed light scattering and low water absorption as discussed above, making it a highly beneficial region for fluorescence imaging with deep tissue penetration and high contrast. Nevertheless, Nd3+ singly doped nanocrystals fail to meet this longer wavelength. The longer emission wavelength within the sub-region can be generated by Er3+ (1525 nm) activator.[56,73] A core/multishell nanostructure using seed-mediated epitaxial growth method was adopted to obtain the highest emission efficiency. Thanks to the advantages in this subregion, a significantly deeper penetration depth (≈18 mm) after covered with various thickness of pork muscle was obtained, as comparing with Nd3+-based nanocrystals emission at 1060 nm. After coating with amphiphilic phospholipids, these biocompatible Er3+-based nanocrystals also performed higher in vivo fluorescence signals in stomach on nude mice at lower concentrations (Figure 3E).[57] In addition, intrinsic emitting at 1525 nm of Er3+ under 808 nm excitation could also be realized in a simple core/shell structure. These bright nanocrystals with a high quantum yield of 11% showed high contrast in vitro imaging of HeLa cells and in vivo through-skull imaging of blood vessels without producing any local heating.[74]\nTo further enhance the emission efficiency of Er3+-based NIR-II nanocrystals, boosting the down-shifting process or increasing the exogenous harvested energy appears to be two highly effective methods. By codoping with Ce3+, the lifetime of 4I11/2 for Er3+ is shortened due to the cross relaxation between Ce3+ and Er3+, resulting in suppressing the upconversion pathway (depopulation of emissive 2H11/2, 4S3/2, and 4F9/2 levels) while enhancing the down-shifting process (population of 4I13/2 level through nonradiative relaxation) (Figure 3F).[53,75] The optimal concentration of 2% Ce3+ doping provided a ninefold enhancement of Er3+ NIR-II emission.[53] Alternatively, owing to the large absorption cross-section (four orders higher than that of common Ln3+ sensitizers), organic dyes can be employed as exogenous antennas to harvest the excitation light in a broad range and transfer the energy to the sensitizers (Figure 3G, left).[76] This antenna effect using ICG induced four times increment in excitation intensity (Figure 3G, right), leading to great emission enhancement of the lanthanide-based NIR-II nanocrystals with a penetration depth of 22 mm thick tissue.[76] In most bioimaging applications using Er3+-based NIR-II nanocrystals, an inevitable disadvantage is that the intensity of 1525 nm is always quenched by OH− groups in aqueous solution when converting the hydrophobic nanocrystals to hydrophilic ones. This is because the fundamental stretching vibration frequencies of OH− groups (2700–3700 cm−1) is about half of the energy spacing of Er3+ for 1525 nm emission (≈6500 cm−1), thus leading to a two-phonon quenching mechanism. To overcome these issues, the most common method is to increase the distance between sensitizers/activators and surface quenchers by coating an inert shell.[77] Unlike the conventional shell coating to protect the upconversion fluorescence, in which a shell of 3 nm thick is adequate in both organic and aqueous solution,[78] the protection of downshifting fluorescence needed a thicker inert shell up to 8 nm to get the brightest fluorescence signal.[53] After PMH coating and\nPEGylation procedure, the biocompatible NIR-II nanocrystals with enhanced intensity showed fast in vivo imaging of blood vasculature in the mouse brain with high SNR (7.3) and short exposure time (20 ms) (Figure 3H).\nAs discussed above, emissions in NIR-II region favor advances in accurate deeper bioimaging. Apparently, this can be further improved if the excitation wavelengths are also extended to the NIR-II window.[1,30] Since the excitation wavelength of previously reported lanthanide-based NIR-II nanocrystals are confined mainly within ≈700–1000 nm, much efforts are being made to the other Ln3+ sensitizers that can be excited at a longer wavelength. Up to now, only a little work has been carried out on the NIR-II to NIR-II luminescence using lanthanide-based NIR-II nanocrystals, in which Er3+ is chosen as the sensitizer under excitation of 1530 nm.[34,35] The Ln3+ activators sensitized by Er3+ to give NIR-II emissions are limited to only Ho3+ (1185 nm), Nd3+ (1060 nm), and Tm3+ (1475 nm). Due to higher water absorbance at ≈1475 nm than that at 980 nm, severe overheating problems may impede the wide use of 1525 nm excitation in biological applications. Nevertheless, due to the fact that absorption preferentially suppresses the noise (photons having longer path length) over the image (ballistic photons), imaging at the peak absorbance of water can provide the highest image contrast, but certainly at the cost of decreasing the overall signal intensity.[79] Thus it can be noted that new fluorophores with brighter NIR-II to NIR-II luminescence signal may open new bioimaging avenues and push the limit of in vivo fluorescence imaging clarity and penetration depth."
    }, {
      "heading" : "5. Lanthanide-Based NIR-II Nanocrystals for Multiplexed Imaging",
      "text" : "To date, imaging with lanthanide-based NIR-II nanocrystals has been primarily focused on longer wavelengths to improve signal with deep penetration and high resolution for small animal models. Despite the large number of achievements obtained in the NIR-II region, in vivo multiplexed (IVM) imaging is still a big challenge for spectra because of the limited number of fluorescent probes and the complex tissue structures. So far, only a few researchers have reported IVM imaging based on two probes at a time[25,32] or one probe with different lifetime.[80] However, neither of the work realizes assessment of quantitative accuracy.\nMost recently, our group[81] has presented a luminescence lifetime multiplexed detection/imaging approach based on lanthanide-doped NIR-II nanocrystals with selectable luminescence lifetimes. We devised a core/multishell structure using seed-mediated epitaxial shell growth method, which absorbs 808 nm photons to generate emission centered at 1525 nm through efficient Nd3+→Yb3+→Er3+ energy transfer (Figure 4A). This structure consists of four parts, including inert core (NaGdF4), activation layer (NaGdF4:Yb/Er), energy relay layer (NaYF4:Yb), and the outer absorption layer (NaNdF4:Yb). Therefore, lifetime of this NaGdF4@NaGdF4:Yb/Er@NaYF4:Yb@ NaNdF4:Yb nanocrystals (Er nanocrystals) is allowed to be tuned systematically in both directions: i) longer lifetime will be generated through increasing the thickness of the energy relay layer, which prolongs the average process from absorption to\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (9 of 14)\nwww.advopticalmat.de\nemission; ii) shorter lifetime can be obtained if the Er3+ concentration increases due to the acceleration of stored energy converting to luminescence emission. Through this systematic approach of controlled energy relay method, an unprecedented dynamic ranges spanning three orders of magnitude for lifetime tuning upon the Er3+ emission band. Using our timeresolved imaging system, more than 10 distinct lifetime identities are easily accommodated at single emission wavelength of 1525 nm (Figure 4B). The universality of the energy relay for tuning lifetime is also accommodated to other Ln3+ (Ln = Ho, Pr, Tm, and Nd) emitting in the NIR-II window. When compared with conventional spectral channel for deep tissue imaging, the lifetimes remained consistent and could be robustly detected even when the signal-to-noise ratio of conventional intensity measurement drops below 1.5, conforming the reliability of lifetime imaging (Figure 4C). We also demonstrated robust lifetime barcoding of individual microscopic information carriers irrelevant to the tissue penetration depth,\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (10 of 14)\nwww.advopticalmat.de\noffering a large multiplexing capacity potentially of 105 unique optical identities. This lifetime multiplexing approach was finally explored for breast cancer diagnostics in vivo. The results of our IVM quantification of tumor biomarker expressions correlated well with conventional western blot (WB) and immunohistochemistry (IHC) tests (Figure 4D). Notably, compared to IHC, IVM can simultaneously quantify multiple biomarkers of tumor to minimize uncertainty caused by the artificial sample processing and scoring procedures, and also eliminate the risk of tumor cell reseeding following biopsy.\nThese results highlight the potential of lifetime in NIR-II region for multiplexing in vivo imaging with accurate quantification, which is impractical to be performed in the spectra domain due to the wavelength-dependent attenuation from different biological tissues. More importantly, pulsed excitation and time-gating techniques employed in lifetime imaging favor high sensitivity by reducing autofluorescence background and thermal effects, enabling the use of higher-power laser. Such approach has addressed the challenge of multiplexed in vivo imaging to an extent and we believe this may provide new ideas for efficient deeper bioimaging with superior NIR-II optical properties."
    }, {
      "heading" : "6. Lanthanide-Based NIR-II Nanocrystals for Biosensing",
      "text" : "The rapid development of sensitive, inexpensive, and facile analytical strategies have accelerated the update of various kinds of optical probes. In addition to biomedical imaging, lanthanidebased NIR-II nanocrystals have also been proposed as effective nanoprobes for biosensing.[34,75,82–84] The mechanisms are usually based on changing the internal valence state distribution of certain Ln3+ (e.g., Ce3+/Ce4+) to respond to surroundings or using lanthanide-based nanocomposites by virtue of exogenous organic probes. For example, Lei et al.[75] reported monodisperse Yb3+/Er3+ doped NaCeF4 nanocrystals, which exhibited enhanced luminescence of Er3+ at 1530 nm upon excitation at 980 nm by the cross-relaxation of codoped Ce3+. After being treated with acid, Ce3+ in the host was exposed on the surface of the ligand-free nanocrystals, which could be directly oxidized to Ce4+ through redox reaction with H2O2 (Figure 5A).[75,85] Therefore, NIR-II emission of Er3+ would be quenched followed by the decreasing of Ce3+. Benefiting from this redox reaction, the nanocrystals were demonstrated as sensitive bioprobes to detect H2O2 products produced by the uric acid and uricase reaction, thus enabling to detect uric acid indirectly (Figure 5B). Taking advantage of H2O2-responsive mechanism, the limit of detection of uric acid was achieved down to 25.6 nm. Recently, our group reported a novel type of Nd3+-based NIR-II mesoporous microcarrier to monitor gastrointestinal protein drug release in vivo (Figure 5C, left).[82] Upon the excitation at 730 and 808 nm, emission at 1060 nm in NIR-II region from Nd3+ was generated in the microcarrier. To track the microcarrier fate and semi-quantitatively monitor the drug-release percentage, an absorption competition–induced emission (ACIE) bioimaging system was rationally designed utilizing the NPTAT organic dye. NPTAT possesses higher absorption coefficient (≈2000-fold) than that of the microcarrier at 730 nm (Figure 5C, right).\nTherefore, the drug-release process can be easily monitored with NIR-II bioimaging at 1060 nm under 730 nm excitation, the signal of which can be quenched by NPTAT with a positive correlation. Meanwhile, NPTAT barely absorbs 808 nm light (Figure 5C, right), thus NIR-II bioimaging at 1060 nm can also be used to track the fate of the microcarriers and as a reference to estimate the release percentage in real-time under 808 nm excitation. The NIR-II imaging results showed that the protein drugs–loaded microcarriers were stable in the stomach and duodenum with acid environment, while sustained release of the drugs happened in the alkaline environment of intestine. Moreover, almost all the microcarriers (>99%) could reside in the intestine for up to three days, during which ≈62% of the protein drugs were effectively released and activity of the released enzymes was largely preserved. Meanwhile, little leakage (<0.1%) of the microcarriers were spotted in liver, spleen, and kidney. In another work,[34] we reported a new type of Er3+ sensitized upconversion nanoparticles (UCNPs) NaErF4:Ho@ NaYF4 with both excitation (1530 nm from Er3+) and emission (1180 nm from Ho3+ and 980 nm from Er3+) in the NIR-II region for in vivo inflammation (H2O2) sensing (Figure 5D, left). The system was fabricated by encapsulating the UCNPs, the H2O2-sensitive IR1061 organic dye, and Fe2+ with Fenton reaction activity in polycaprolactone. Under 1530 nm excitation, emission at 980 nm is greatly suppressed due to the strong absorption (800–1100 nm) of IR1061 (Figure 5D, right). However, this “shielding effect” will be weakened when IR1061 is destructed by the localized ·OH radical generated from H2O2, leading to the recovery of 980 nm emission (Figure 5D, left). In this sensing process, the intensity of 1180 nm, which is out of the absorption region of IR1061 (Figure 5D, right), remained stable (Figure 5D, left). Therefore, the ratiometric fluorescence (I980/I1180) can reflect H2O2 concentration indirectly due to the positive correlation relationship according to the Lambert–Beer law. With this mechanism, a microneedle sensor at 200*200 µm resolution was fabricated and dynamically evaluated in vivo infammination successfully (Figure 5E). Noteworthy, to build effective biosensors based on lantnaide– organic nanocomposites, several criteria should be considered: i) a probe and a absorber are necessary; ii) the probes need to have multiexcitation bands or emission bands under single/ multiexcitations; iii) the absorption band of the absorbers need to overlap with only one of the excitation or emission band of the probe, while the others are unaffected; iv) the absorbers should have a higher molar absorption coefficient and respond to the local surroundings. Combining with advances of NIR-II imaging, these smart nanoprobes may provide novel insights for extended applications."
    }, {
      "heading" : "7. Conclusions and Outlook",
      "text" : "In the last decade, NIR-II probes played an important role in bioimaging and biodetection due to their intrinsic advantages against traditional imaging probes. The former existing NIR-II probes suffer from large-size and broad emission spectra (e.g., SWNTs), low solubility in aqueous solution (e.g., small molecules and conjugated polymers), unfavorably short emission wavelength (e.g., small molecules), and potential toxity\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (11 of 14)\nwww.advopticalmat.de\n(e.g., QDs). As one of the major categories of contrast agents for biomedical imaging in the NIR-II channel, lanthanide-based nanocrystals favor low photobleaching, nonblinking, absence of autofluorescence, long luminescence lifetimes, low long-term cytotoxicity, large (anti-)Stokes shift, and remarkable ability to penetrate light in tissues, which play a vital role in increasing long-term luminescence and multispectral imaging in diverse fields. Nevertheless, a relatively low fluorescence quantum yield, difficult to large-scale synthesis, and latent toxicity of these nanocrystals also cannot be ignored in practical applications. The development of lanthanide-based NIR-II nanocrystals must take into account a variety of design parameters and ultimately be tailored according to the specific biomedical application. Recently, the successes made by bioimaging using emergence of these lanthanide nanocrystals have enriched our understanding and addressed the limitation of deep imaging to a certain extent. Here, we would like to highlight some future directions for lanthanide-based NIR-II nanocrystals to enrich the wide applications in clinic studies: (i) Lanthanide elements are spectroscopically rich species and have not been well studied yet. Currently, only a handful lanthanide-based NIR-II nanocrystals (e.g., Er3+ at 1525 nm and Nd3+ at 1060 nm) with limited excitation wavelengths (e.g., Nd3+ at 808 nm and Yb3+ at 980 nm) have been studied and applied to preclinical imaging in experimental animal models. Thus, it is an urgent task to explore more nanocrystals with tunable emission and excitation wavelengths in the\nAdv. Optical Mater. 2019, 1801417\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (12 of 14)\nwww.advopticalmat.de\nAdv. Optical Mater. 2019, 1801417\nfavorable >1000 nm region for deeper penetration depth and higher spatial resolution. (ii) Another concern of the lanthanide-based NIR-II nanocrystals is the relatively low quantum yield due to the high surface area, limiting the effective penetration depth to a few centimeters. Yet, it also means there still be a large room for further improvement. Although rational strategies have been adopted to increase the quantum yield of these nanocrystals, such as core/shell construction, surface-plasmon coupling and organic dye-sensitization, new strategies are still imperative since the above complicated strategies made it difficult to synthesize sub-10 nm nanocrystals. (iii) Although much work has been carried out on bioimaging with remarkable outcomes, lanthanide self-based biosensing in NIR-II region is still in its infancy, mainly focusing on changing the internal valence state of limited Ln3+ (e.g., Ce3+). Thus, it is a big challenge to develop much smarter lanthanide-based probes for biosensing applications. To seek the way, nanocomposites may give us the inspiration by virtue of the fast developing organic dyes in NIR-II region as discussed above, which can endow the lanthanide-based nanocrystals with new exciting functions for wide applications in biosensing. (iv) Cytotoxicity is also the significant concern to the lanthanidebased NIR-II nanocrystals. Owing to unknown long-term toxicity, a key characteristics of the imaging probes for future clinical uses is the ability to rapid excretion. Therefore, ultrasmall nanocrystals within the renal filtration threshold of ≈40 kD may show enormous potential from bench to bedside, which, however, will also be hampered by the following low quantum efficiency when decreasing the size of the nanocrystals. Thus, exploring brighter and smaller imaging probes will become the future directions. Recently, NIR-II probes based on lanthanide complex with much small size (<1 kD) have also attracted significant attention, which may play a key role in NIR-II bioimaging.[86,87] (v) Lifetime imaging in the NIR-II region is a rather new imaging modality. It enables quantitative multiplexing in vivo due to its stability in complex tissue structures, which is usually impractical for conventional imaging based on spectra. Although promising in intraoperative diagnosis and guidance of surgical procedures, lifetime imaging is failed to monitor fast characteristic biomedical changes due to the delayed lifetime measurement. This may be improved by using brighter nanocrystals with shorter lifetimes (e.g., small organic dye with lifetime in the nanosecond range) and new arithmetic for obtaining lifetime (e.g., phase modulation), which may speed up the data acquisition to realize imaging in real-time. Considering the above points, lanthanide-based NIR-II nanocrystals may hold a great promising future."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The work was supported by the National Key R & D Program of China (2017YFA0207303), National Science Fund for Distinguished Young Scholars (21725502), Key Basic Research Program of Science and Technology Commission of Shanghai Municipality (17JC1400100), and China Postdoctoral Science Foundation (Grant KLH1615151)."
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Keywords",
      "text" : "bioimaging, fluorescence, lanthanides, nanoparticles, near infrared imaging, NIR-II\nReceived: October 16, 2018 Revised: December 18, 2018\nPublished online:\n[1] G. S. Hong, A. L. Antaris, H. J. Dai, Nat. Biomed. Eng. 2017, 1, 0010. [2] X. L. Zhang, Y. L. Tian, C. Zhang, X. Y. Tian, A. W. Ross, R. D. Moir, H. B. Sun, R. E. Tanzi, A. Moore, C. Z. Ran, Proc. Natl. Acad. Sci. USA 2015, 112, 9734. [3] N. G. Horton, K. Wang, D. Kobat, C. G. Clark, F. W. Wise, C. B. Schaffer, C. Xu, Nat. Photonics 2013, 7, 205. [4] V. Ntziachristos, J. Ripoll, L. H. V. Wang, R. Weissleder, Nat. Biotechnol. 2005, 23, 313. [5] A. Galperin, D. Margel, J. Baniel, G. Dank, H. Biton, S. Margel, Biomaterials 2007, 28, 4461. [6] A. K. Buck, S. Nekolla, S. Ziegler, A. Beer, B. J. Krause, K. Herrmann, K. Scheidhauer, H. J. Wester, E. J. Rummeny, M. Schwaiger, A. Drzezga, J. Nucl. Med. 2008, 49, 1305. [7] R. Bar-Shalom, N. Yefremov, L. Guralnik, D. Gaitini, A. Frenkel, A. Kuten, H. Altman, Z. Keidar, O. Israel, J. Nucl. Med. 2003, 44, 1200. [8] B. J. Pichler, H. F. Wehrl, M. S. Judenhofer, J. Nucl. Med. 2008, 49, 5S. [9] B. J. Pichler, A. Kolb, T. Nagele, H. P. Schlemmer, J. Nucl. Med. 2010, 51, 333. [10] O. M. Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, M. Behe, T. Kissel, Bioconjugate Chem. 2009, 20, 174. [11] A. N. Bashkatov, E. A. Genina, V. I. Kochubey, V. V. Tuchin, J. Phys. D: Appl. Phys. 2005, 38, 2543. [12] R. Weissleder, Nat. Biotechnol. 2001, 19, 316. [13] A. M. Smith, M. C. Mancini, S. M. Nie, Nat. Nanotechnol. 2009, 4,\n710. [14] W. P. Fan, B. Shen, W. B. Bu, F. Chen, Q. J. He, K. L. Zhao,\nS. J. Zhang, L. P. Zhou, W. J. Peng, Q. F. Xiao, D. L. Ni, J. N. Liu, J. L. Shi, Biomaterials 2014, 35, 8992. [15] H. Y. Xing, W. B. Bu, Q. G. Ren, X. P. Zheng, M. Li, S. J. Zhang, H. Y. Qu, Z. Wang, Y. Q. Hua, K. L. Zhao, L. P. Zhou, W. J. Peng, J. L. Shi, Biomaterials 2012, 33, 5384. [16] X. M. Li, R. Wang, F. Zhang, L. Zhou, D. K. Shen, C. Yao, D. Y. Zhao, Sci. Rep. 2013, 3, 3536. [17] A. L. Vahrmeijer, M. Hutteman, J. R. van der Vorst, J. H. van de Velde, J. V. Frangioni, Nat. Rev. Clin. Oncol. 2013, 10, 507. [18] T. Ishizawa, N. Fukushima, J. Shibahara, K. Masuda, S. Tamura, T. Aoki, K. Hasegawa, Y. Beck, M. Fukayama, N. Kokudo, Cancer 2009, 115, 2491. [19] K. Polom, D. Murawa, Y. S. Rho, P. Nowaczyk, M. Hünerbein, P. Murawa, Cancer 2011, 117, 4812. [20] S. Diao, G. S. Hong, A. L. Antaris, J. L. Blackburn, K. Cheng, Z. Cheng, H. J. Dai, Nano Res. 2015, 8, 3027. [21] G. S. Hong, J. C. Lee, J. T. Robinson, U. Raaz, L. M. Xie, N. F. Huang, J. P. Cooke, H. J. Dai, Nat. Med. 2012, 18, 1841.\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (13 of 14)\nwww.advopticalmat.de\nAdv. Optical Mater. 2019, 1801417\n[22] Y. Tsukasaki, A. Komatsuzaki, Y. Mori, Q. Ma, Y. Yoshioka, T. Jin, Chem. Commun. 2014, 50, 14356. [23] J. H. Park, L. Guo, G. von Maltzahn, E. Ruoslahti, S. N. Bhatia, M. J. Sailor, Nat. Mater. 2009, 8, 331. [24] G. S. Hong, J. T. Robinson, Y. J. Zhang, S. Diao, A. L. Antaris, Q. B. Wang, H. J. Dai, Angew. Chem., Int. Ed. 2012, 51, 9818. [25] O. T. Bruns, T. S. Bischof, D. K. Harris, D. Franke, Y. X. Shi, L. Riedemann, A. Bartelt, F. B. Jaworski, J. A. Carr, C. J. Rowlands, M. W. B. Wilson, O. Chen, H. Wei, G. W. Hwang, D. M. Montana, I. Coropceanu, O. B. Achorn, J. Kloepper, J. Heeren, P. T. C. So, D. Fukumura, K. F. Jensen, R. K. Jain, M. G. Bawendi, Nat. Biomed. Eng. 2017, 1, 0056. [26] D. Ghosh, A. F. Bagley, Y. J. Na, M. J. Birrer, S. N. Bhatia, A. M. Belcher, Proc. Natl. Acad. Sci. USA 2014, 111, 13948. [27] M. H. Wong, J. P. Giraldo, S. Y. Kwak, V. B. Koman, R. Sinclair, T. T. S. Lew, G. Bisker, P. W. Liu, M. S. Strano, Nat. Mater. 2017, 16, 264. [28] N. M. Iverson, P. W. Barone, M. Shandell, L. J. Trudel, S. Sen, F. Sen, V. Ivanov, E. Atolia, E. Farias, T. P. McNicholas, N. Reuel, N. M. A. Parry, G. N. Wogan, M. S. Strano, Nat. Nanotechnol. 2013, 8, 873. [29] A. L. Antaris, H. Chen, K. Cheng, Y. Sun, G. S. Hong, C. R. Qu, S. Diao, Z. X. Deng, X. M. Hu, B. Zhang, X. D. Zhang, O. K. Yaghi, Z. R. Alamparambil, X. C. Hong, Z. Cheng, H. J. Dai, Nat. Mater. 2016, 15, 235. [30] B. H. Li, L. F. Lu, M. Y. Zhao, Z. H. Lei, F. Zhang, Angew. Chem., Int. Ed. 2018, 57, 7483. [31] G. S. Hong, Y. P. Zou, A. L. Antaris, S. Diao, D. Wu, K. Cheng, X. D. Zhang, C. X. Chen, B. Liu, Y. H. He, J. Z. Wu, J. Yuan, B. Zhang, Z. M. Tao, C. Fukunaga, H. J. Dai, Nat. Commun. 2014, 5, 4206. [32] D. J. Naczynski, M. C. Tan, M. Zevon, B. Wall, J. Kohl, A. Kulesa, S. Chen, C. M. Roth, R. E. Riman, P. V. Moghe, Nat. Commun. 2013, 4, 2199. [33] F. Liégard, J. L. Doualan, R. Moncorgé, M. Bettinelli, Appl. Phys. B 2005, 80, 985. [34] L. Liu, S. F. Wang, B. Z. Zhao, P. Pei, Y. Fan, X. M. Li, F. Zhang, Angew. Chem., Int. Ed. 2018, 57, 7518. [35] X. W. Cheng, Y. Pan, Z. Yuan, X. W. Wang, W. H. Su, L. S. Yin, X. J. Xie, L. Huang, Adv. Funct. Mater. 2018, 28, 1800208. [36] H. Dong, S. R. Du, X. Y. Zheng, G. M. Lyu, L. D. Sun, L. D. Li, P. Z. Zhang, C. Zhang, C. H. Yan, Chem. Rev. 2015, 115, 10725. [37] F. Wang, X. G. Liu, Chem. Soc. Rev. 2009, 38, 976. [38] X. M. Li, F. Zhang, D. Y. Zhao, Chem. Soc. Rev. 2015, 44, 1346. [39] G. Y. Chen, H. L. Qiu, P. N. Prasad, X. Y. Chen, Chem. Rev. 2014,\n114, 5161. [40] J. Zhou, Q. Liu, W. Feng, Y. Sun, F. Y. Li, Chem. Rev. 2015, 115,\n395. [41] U. Rocha, K. U. Kumar, C. Jacinto, I. Villa, F. Sanz-Rodríguez,\nM. D. C. I. de la Cruz, A. Juarranz, E. Carrasco, F. C. J. M. van Veggel, E. Bovero, J. G. Solé, D. Jaque, Small 2014, 10, 1141. [42] G. Y. Chen, T. Y. Ohulchanskyy, S. Liu, W. C. Law, F. Wu, M. T. Swihart, H. Ågren, P. N. Prasad, ACS Nano 2012, 6, 2969. [43] I. Villa, A. Vedda, I. X. Cantarelli, M. Pedroni, F. Piccinelli, M. Bettinelli, A. Speghini, M. Quintanilla, F. Vetrone, U. Rocha, C. Jacinto, E. Carrasco, F. S. Rodríguez, Á. Juarranz, B. del Rosal, D. H. Ortgies, P. H. Gonzalez, J. G. Solé, D. J. García, Nano Res. 2015, 8, 649. [44] A. Bednarkiewicz, D. Wawrzynczyk, M. Nyk, W. Strek, Opt. Mater. 2011, 33, 1481. [45] X. Y. Jiang, C. Cao, W. Feng, F. Y. Li, J. Mater. Chem. B 2016, 4, 87. [46] F. Ren, L. H. Ding, H. H. Liu, Q. Huang, H. Zhang, L. J. Zhang,\nJ. F. Zeng, Q. Sun, Z. Li, M. Y. Gao, Biomaterials 2018, 175, 30. [47] X. F. Yu, L. D. Chen, M. Li, M. Y. Xie, L. Zhou, Y. Li, Q. Q. Wang,\nAdv. Mater. 2008, 20, 4118.\n[48] B. del Rosal, A. Pérez-Delgado, M. Misiak, A. Bednarkiewicz, A. S. Vanetsev, Y. Orlovskii, D. J. Jovanović, M. D. Dramićanin, U. Rocha, K. Upendra Kumar, C. Jacinto, E. Navarro, E. Martín Rodríguez, M. Pedroni, A. Speghini, G. A. Hirata, I. R. Martín, D. Jaque, J. Appl. Phys. 2015, 118, 143104. [49] G. Y. Chen, T. Y. Ohulchanskyy, A. Kachynski, H. Ågren, P. N. Prasad, ACS Nano 2011, 5, 4981. [50] A. Shalav, B. S. Richards, T. Trupke, K. W. Krämer, H. U. Güdel, Appl. Phys. Lett. 2005, 86, 013505. [51] X. Y. Du, X. F. Wang, L. Meng, Y. Y. Bu, X. H. Yan, Nanoscale Res. Lett. 2017, 12, 163. [52] N. J. J. Johonson, S. He, S. Diao, E. M. Chan, H. J. Dai, A. Almutairi, J. Am. Chem. Soc. 2017, 139, 3275. [53] Y. T. Zhong, Z. R. Ma, S. J. Zhu, J. Y. Yue, M. X. Zhang, A. L. Antaris, J. Yuan, R. Cui, H. Wan, Y. Zhou, W. Z. Wang, N. F. Huang, J. Luo, Z. Y. Hu, H. J. Dai, Nat. Commun. 2017, 8, 737. [54] H. Kantamneni, M. Zevon, M. J. Donzanti, X. Y. Zhao, Y. Sheng, S. R. Barkund, L. H. McCabe, W. Banach-Petrosky, L. M. Higgins, S. Ganesan, R. E. Riman, C. M. Roth, M. C. Tan, M. C. Pierce, V. Ganapathy, P. V. Moghe, Nat. Biomed. Eng. 2017, 1, 993. [55] C. S. Ma, X. X. Xu, F. Wang, Z. G. Zhou, D. M. Liu, J. B. Zhao, M Guan, C. I. Lang, D. Y. Jin, Nano Lett. 2017, 17, 2858. [56] J. A. Damasco, G. Y. Chen, W. Shao, H. Ågren, H. Y. Huang, W. T. Song, J. F. Lovell, P. N. Prasad, ACS Appl. Mater. Interfaces 2014, 6, 13884. [57] R. Wang, X. M. Li, L. Zhou, F. Zhang, Angew. Chem., Int. Ed. 2014, 53, 12086. [58] T. Y. Sun, R. H. Ma, X. S. Qiao, X. P. Fan, F. Wang, ChemPhysChem 2016, 17, 766. [59] R. D. Shannon, Acta Crystallogr. A 1976, 32, 751. [60] F. Wang, Y. Han, C. S. Lim, Y. H. Lu, J. Wang, J. Xu, H. Y. Chen,\nC. Zhang, M. H. Hong, X. G. Liu, Nature 2010, 463, 1061. [61] Q. Liu, Y. X. Zhang, C. S. Peng, T. S. Yang, L. M. Joubert, S. Chu,\nNat. Photonics 2018, 12, 548. [62] X. Chen, L. M. Jin, W. Kong, T. Y. Sun, W. F. Zhang, X. H. Liu, J. Fan,\nS. F. Yu, F. Wang, Nat. Commun. 2016, 7, 10304. [63] R. K. Shi, X. C. Ling, X. N. Li, L. Zhang, M. Lu, X. J. Xie, L. Huang,\nW. Huang, Nanoscale 2017, 9, 13739. [64] J. Shen, G. Y. Chen, A. M. Vu, W. Fan, O. S. Bilsel, C. C. Chang,\nG. Han, Adv. Opt. Mater. 2013, 1, 644. [65] Y. F. Wang, G. Y. Liu, L. D. Sun, J. W. Xiao, J. C. Zhou, C. H. Yan,\nACS Nano 2013, 7, 7200. [66] X. J. Xie, N. Y. Gao, R. R. Deng, Q. Sun, Q. H. Xu, X. G. Liu, J. Am.\nChem. Soc. 2013, 135, 12608. [67] Y. T. Zhong, G. Tian, Z. J. Gu, Y. J. Yang, L. Gu, Y. L. Zhao, Y. Ma,\nJ. N. Yao, Adv. Mater. 2014, 26, 2831. [68] M. Kamimura, N. Kanayama, K. Tokuzen, K. Soga, Y. Nagasaki,\nNanoscale 2011, 3, 3705. [69] Z. M. Deng, Z. L. Li, Z. L. Xue, M. Y. Jiang, Y. B. Li, S. J. Zeng,\nH. R. Liu, Nanoscale 2018, 10, 9393. [70] X. N. Dang, L. Gu, J. F. Qi, S. Correa, G. Zhang, A. M. Belcher,\nP. T. Hammond, Proc. Natl. Acad. Sci. USA 2016, 113, 5179. [71] P. Y. Wang, Y. Fan, L. F. Lu, L. Liu, L. L. Fan, M. Y. Zhao, Y. Xie,\nC. J. Xu, F. Zhang, Nat. Commun. 2018, 9, 2898. [72] L. Gu, D. J. Hall, Z. T. Qin, E. Anglin, J. Joo, D. J. Mooney,\nS. B. Howell, M. J. Sailor, Nat. Commun. 2013, 4, 3326. [73] Z. L. Xue, S. J. Zeng, J. H. Hao, Biomaterials 2018, 171, 153. [74] X. Wang, A. Yakovliev, T. Y. Ohulchanskyy, L. Wu, S. J. Zeng,\nX. J. Han, J. L. Qu, G. Y. Chen, Adv. Opt. Mater. 2018, 6, 1800690. [75] X. L. Lei, R. F. Li, D. T. Tu, X. Y. Shang, Y. Liu, W. W. You, C. X. Sun,\nF. Zhang, X. Y. Chen, Chem. Sci. 2018, 9, 4682. [76] W. Shao, G. Y. Chen, A. Kuzmin, H. L Kutscher, A. Pliss,\nT. Y. Ohulchanskyy, P. N. Prasad, J. Am. Chem. Soc. 2016, 138, 16192.\n[77] G. S. Yi, G. M. Chow, Chem. Mater. 2007, 19, 341.\nwww.advancedsciencenews.com\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1801417 (14 of 14)\nwww.advopticalmat.de\nAdv. Optical Mater. 2019, 1801417\n[78] F. Zhang, R. C. Che, X. M. Li, C. Yao, J. P. Yang, D. K. Shen, P. Hu, W. Li, D. Y. Zhao, Nano Lett. 2012, 12, 2852. [79] J. A. Carr, M. Aellen, D. Franke, P. T. C. So, O. T. Bruns, M. G. Bawendi, Proc. Natl. Acad. Sci. USA 2018, 115, 9080. [80] D. H. Ortgies, M. L. Tan, E. C. Ximendes, B. del Rosal, J. Hu, L. Xu, X. D. Wang, E. M. Rodríguez, C. Jacinto, N. Fernandez, G. Y. Chen, D. Jaque, ACS Nano 2018, 12, 4362. [81] Y. Fan, P. Y. Wang, Y. Q. Lu, R. Wang, L. Zhou, X. L. Zheng, X. M. Li, J. A. Piper, F. Zhang, Nat. Nanotechnol. 2018, 13, 941. [82] R. Wang, L. Zhou, W. X. Wang, X. M. Li, F. Zhang, Nat. Commun. 2017, 8, 17402. [83] A. Skripka, A. Benayas, R. Marin, P. Canton, E. Hemmer, F. Vetrone, Nanoscale 2017, 9, 3079. [84] M. Kaminura, T. Matsumoto, S. Suyari, M. Umezawa, K. Soga, J. Mater. Chem. B 2017, 5, 1917. [85] Y. N. Huang, Q. B. Xiao, J. Wang, Y. L. Xi, F. J. Li, Y. M. Feng, L. Y. Shi, H. Z. Lin, J. Lumin. 2016, 173, 66. [86] Y. L. Yang, P. Y. Wang, L. F. Lu, Y. Fan, C. X. Sun, L. L. Fan, C. J. Xu, A. M. El-Toni, M. Alhoshan, F. Zhang, Anal. Chem. 2018, 90, 7946. [87] Y. B. Li, X. L. Li, Z. L. Xue, M. Y. Jiang, S. J. Zeng, J. H. Hao, Biomaterials 2018, 169, 35."
    } ],
    "references" : [ {
      "title" : "Med",
      "author" : [ "A.K. Buck", "S. Nekolla", "S. Ziegler", "A. Beer", "B.J. Krause", "K. Herrmann", "K. Scheidhauer", "H.J. Wester", "E.J. Rummeny", "M. Schwaiger", "A. Drzezga", "J. Nucl" ],
      "venue" : "2008, 49,",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 1305
    }, {
      "title" : "Med",
      "author" : [ "R. Bar-Shalom", "N. Yefremov", "L. Guralnik", "D. Gaitini", "A. Frenkel", "A. Kuten", "H. Altman", "Z. Keidar", "O. Israel", "J. Nucl" ],
      "venue" : "2003, 44,",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 1200
    }, {
      "title" : "D: Appl",
      "author" : [ "A.N. Bashkatov", "E.A. Genina", "V.I. Kochubey", "V.V. Tuchin", "J. Phys" ],
      "venue" : "Phys. 2005, 38,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2543
    }, {
      "title" : "Chem",
      "author" : [ "M. Kaminura", "T. Matsumoto", "S. Suyari", "M. Umezawa", "K. Soga", "J. Mater" ],
      "venue" : "B 2017, 5,",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 1917
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "[1–4] In addition, it does not require hazard ionizing radiation, as compared to routine imaging modalities, such as computed tomography (CT),[5–8] positron emission tomography (PET),[7–9] and single-photon emission computed tomography (SPECT).[6,8,10] It is also known as a noninvasive technique, enabling the real-time acquisition of wide-field images.",
      "startOffset" : 244,
      "endOffset" : 252
    }, {
      "referenceID" : 2,
      "context" : "This is especially evident in the traditional visible range (VIS, 400–700 nm),[1,11,12] which is only feasible for superficial tissues imaging with penetration depth at ≈1 mm.",
      "startOffset" : 78,
      "endOffset" : 87
    }, {
      "referenceID" : 2,
      "context" : "Subsequently, imaging in the first near-infrared window (NIR-I, 700–900 nm),[11,13] traditionally defined as biological transparency window, shows an improved penetration depth with up to several millimeters in biological imaging due to the reduced absorption and scattering coefficient (Figure 1B,C), as photon scattering in biological tissue scaling with λ−ω (λ denotes the wavelength, ω = 0.",
      "startOffset" : 76,
      "endOffset" : 83
    }, {
      "referenceID" : 2,
      "context" : "68 depending on tissues).[11] Although fundamental researches Fluorescence-based imaging in the second near infrared window (NIR-II,",
      "startOffset" : 25,
      "endOffset" : 29
    }, {
      "referenceID" : 2,
      "context" : "To overcome the constraints of imaging in NIR-I region, a new imaging window, namely the second near-infrared window (NIR-II, 1000–1700 nm), has been identified recently after predicted through optical simulations.[11,13] In addition to the further reduced scattering coefficient at a fixed tissue depth as that in NIR-I region, tissue autofluorescence in NIR-II region decreases exponentially and is almost zero when the wavelength is beyond ≈1500 nm (Figure 1D).",
      "startOffset" : 214,
      "endOffset" : 221
    }, {
      "referenceID" : 3,
      "context" : "NaYF4:Yb/Ho/Er 980/1150, 1550 PEG-b-PAAc NIR-II bioimaging and thermal sensing [84]",
      "startOffset" : 79,
      "endOffset" : 83
    } ],
    "year" : 2019,
    "abstractText" : "Recently, fluorescence imaging has been extensively studied and used in life sciences and medical research due to its fast feedback, high sensitivity, and high spatiotemporal resolution.[1–4] In addition, it does not require hazard ionizing radiation, as compared to routine imaging modalities, such as computed tomography (CT),[5–8] positron emission tomography (PET),[7–9] and single-photon emission computed tomography (SPECT).[6,8,10] It is also known as a noninvasive technique, enabling the real-time acquisition of wide-field images. Despite many advantages, key issues in optical imaging lie in the high absorption and scattering of biological tissues as well as high autofluorescence (Figure 1A), leading to low tissue penetration depth and low signal-to-noise ratio (SNR). This is especially evident in the traditional visible range (VIS, 400–700 nm),[1,11,12] which is only feasible for superficial tissues imaging with penetration depth at ≈1 mm. Subsequently, imaging in the first near-infrared window (NIR-I, 700–900 nm),[11,13] traditionally defined as biological transparency window, shows an improved penetration depth with up to several millimeters in biological imaging due to the reduced absorption and scattering coefficient (Figure 1B,C), as photon scattering in biological tissue scaling with λ−ω (λ denotes the wavelength, ω = 0.22–1.68 depending on tissues).[11] Although fundamental researches Fluorescence-based imaging in the second near infrared window (NIR-II, 1000–1700 nm) is extensively used in both fundamental scientific research and clinical practice, owing to its advances of high sensitivity and high spatiotemporal resolution with increasing tissue penetration depths. Among several NIR-II fluorophores, recent accomplishments in biocompatible lanthanidebased luminescent nanomaterials have aroused great interest of researchers. This progress report summarizes recent progress in controlled synthesis of lanthanide-based NIR-II nanomaterials and their state-of-the-art in NIR-II biomedical imaging and biosensing applications. In addition, challenges and opportunities for this kind of novel NIR-II nanoprobes are also discussed. Fluorescence-Based Bioimaging",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}